Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): A population control study

Journal of Neuroimmunology

Volumn 249, Issue 1-2, 2012, Pages 66-70

  Rojana udomsart, Arada ^a,b   Bundell, Christine ^a,c   James, Ian ^d   Castley, Alison ^d   Martinez, Patricia ^a,d   Christiansen, Frank ^a,d   Hollingsworth, Peter ^a,c   Mastaglia, Frank ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Yala Hospital   (Thailand)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Autoantibodies; HLA DRB1 alleles; Inclusion body myositis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; HLA DRB1 ANTIGEN; LA ANTIBODY; MYOSITIS ASSOCIATED ANTIBODY; MYOSITIS SPECIFIC ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO52 ANTIBODY; RO60 ANTIBODY; THYROID PEROXIDASE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; AUTOIMMUNE THYROIDITIS; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; INCLUSION BODY MYOSITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; SJOEGREN SYNDROME; VITILIGO;

ADULT; AGED; AUTOANTIBODIES; AUTOANTIGENS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HLA-DRB1 CHAINS; HUMANS; MALE; MIDDLE AGED; MYOSITIS, INCLUSION BODY; POLYMERASE CHAIN REACTION;

EID: 84863430318     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.04.007     Document Type: Article

References (36)

1. Alaedini A., Green P.H. Autoantibodies in celiac disease. Autoimmunity 2008, 41:19-26.
2. Amemiya K., Granger R.P., Dalakas M.C. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 2000, 123(Pt 10):2030-2039.
3. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 1984, 16:193-208.
4. Arnett F.C., Targoff I.N., Mimori T., Goldstein R., Warner N.B., Reveille J.D. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996, 39:1507-1518.
5. Badrising U.A., Schreuder G.M., Giphart M.J., Geleijns K., Verschuuren J.J., Wintzen A.R., Maat-Schieman M.L., van Doorn P., van Engelen B.G., Faber C.G., Hoogendijk J.E., de Jager A.E., Koehler P.J., de Visser M., van Duinen S.G. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004, 63:2396-2398.
6. Brouwer R., Hengstman G.J., Vree Egberts W., Ehrfeld H., Bozic B., Ghirardello A., Grondal G., Hietarinta M., Isenberg D., Kalden J.R., Lundberg I., Moutsopoulos H., Roux-Lombard P., Vencovsky J., Wikman A., Seelig H.P., van Engelen B.G., van Venrooij W.J. Autoantibody profiles in the sera of European patients with myositis. Ann. Rheum. Dis. 2001, 60:116-123.
7. Chinoy H., Salway F., Fertig N., Shephard N., Tait B.D., Thomson W., Isenberg D.A., Oddis C.V., Silman A.J., Ollier W.E., Cooper R.G. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res. Ther. 2006, 8:R13.
8. Dalakas M.C. Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat. Clin. Pract. Neurol. 2006, 2:437-447.
9. Dalakas M.C. Interplay between inflammation and degeneration: using inclusion body myositis to study "neuroinflammation". Ann. Neurol. 2008, 64:1-3.
10. Dalakas M.C., Illa I., Gallardo E., Juarez C. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann. Neurol. 1997, 41:100-104.
11. Fernandez E., Blanco C., Garcia S., Dieguez A., Riestra S., Rodrigo L. Use of low concentrations of human IgA anti-tissue transglutaminase to rule out selective IgA deficiency in patients with suspected celiac disease. Clin. Chem. 2005, 51:1014-1016.
12. Garlepp M.J., Laing B., Zilko P.J., Ollier W., Mastaglia F.L. HLA associations with inclusion body myositis. Clin. Exp. Immunol. 1994, 98:40-45.
13. Greenberg S.A. Inclusion body myositis. Curr. Opin. Rheumatol. 2011, 23:574-578.
14. Hausmanowa-Petrusewicz I., Kowalska-Oledzka E., Miller F.W., Jarzabek-Chorzelska M., Targoff I.N., Blaszczyk-Kostanecka M., Jablonska S. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997, 40:1257-1266.
15. Hayashi N., Koshiba M., Nishimura K., Sugiyama D., Nakamura T., Morinobu S., Kawano S., Kumagai S. Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod. Rheumatol. 2008, 18:153-160.
16. Hengstman G.J., Brouwer R., Egberts W.T., Seelig H.P., Jongen P.J., van Venrooij W.J., van Engelen B.G. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J. Neurol. 2002, 249:69-75.
17. Hohlfeld R. Update on sporadic inclusion body myositis. Brain 2011, 134:3141-3145.
18. Koffman B.M., Rugiero M., Dalakas M.C. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998, 21:115-117.
19. Lampe J.B., Gossrau G., Kempe A., Fussel M., Schwurack K., Schroder R., Krause S., Kohnen R., Walter M.C., Reichmann H., Lochmuller H. Analysis of HLA class I and II alleles in sporadic inclusion-body myositis. J. Neurol. 2003, 250:1313-1317.
20. Limaye V.S., Lester S., Bardy P., Thompson P., Cox S., Blumbergs P., Roberts-Thomson P. A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis. Rheumatol. Int. 2012, 32:611-619.
21. Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Dalakas M., Plotz P.H., Miller F.W. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
22. Mastaglia F.L. Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC. Acta Myol. 2009, 28:66-71.
23. Mastaglia F.L., Phillips B.A. Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum. Dis. Clin. North Am. 2002, 28:723-741.
24. Needham M., Mastaglia F.L. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol. 2007, 6:620-631.
25. Needham M., Mastaglia F.L., Garlepp M.J. Genetics of inclusion-body myositis. Muscle Nerve 2007, 35:549-561.
26. Needham M., James I., Corbett A., Day T., Christiansen F., Phillips B., Mastaglia F.L. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J. Neurol. Neurosurg. Psychiatry 2008, 79:1056-1060.
27. O'Hanlon T.P., Carrick D.M., Arnett F.C., Reveille J.D., Carrington M., Gao X., Oddis C.V., Morel P.A., Malley J.D., Malley K., Dreyfuss J., Shamim E.A., Rider L.G., Chanock S.J., Foster C.B., Bunch T., Plotz P.H., Love L.A., Miller F.W. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. Medicine (Baltimore) 2005, 84:338-349.
28. O'Hanlon T.P., Carrick D.M., Targoff I.N., Arnett F.C., Reveille J.D., Carrington M., Gao X., Oddis C.V., Morel P.A., Malley J.D., Malley K., Shamim E.A., Rider L.G., Chanock S.J., Foster C.B., Bunch T., Blackshear P.J., Plotz P.H., Love L.A., Miller F.W. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006, 85:111-127.
29. Orbach H., Amitai N., Barzilai O., Boaz M., Ram M., Zandman-Goddard G., Shoenfeld Y. Autoantibody screen in inflammatory myopathies high prevalence of antibodies to gliadin. Ann. N. Y. Acad. Sci. 2009, 1173:174-179.
30. Peter J.B.a.Y.S. Autoantibodies 1996, Elsevier, Amsterdam.
31. Rider L.G., Gurley R.C., Pandey J.P., Garcia de la Torre I., Kalovidouris A.E., O'Hanlon T.P., Love L.A., Hennekam R.C., Baumbach L.L., Neville H.E., Garcia C.A., Klingman J., Gibbs M., Weisman M.H., Targoff I.N., Miller F.W. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis Rheum. 1998, 41:710-719.
32. Schmidt J., Barthel K., Wrede A., Salajegheh M., Bahr M., Dalakas M.C. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008, 131:1228-1240.
33. Scott A.P., Laing N.G., Mastaglia F., Needham M., Walter M.C., Dalakas M.C., Allcock R.J. Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex. J. Neuroimmunol. 2011, 235:77-83.
34. Selva-O'Callaghan A., Labrador-Horrillo M., Solans-Laque R., Simeon-Aznar C.P., Martinez-Gomez X., Vilardell-Tarres M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum. 2006, 55:791-798.
35. Selva-O'Callaghan A., Casellas F., de Torres I., Palou E., Grau-Junyent J.M., Vilardell-Tarres M. Celiac disease and antibodies associated with celiac disease in patients with inflammatory myopathy. Muscle Nerve 2007, 35:49-54.
36. Welborn T. The Busselton Study: Mapping Population Health Cardiovascular and Respiratory Disease Risk Factors in Busselton, Australia 1998 1998, Australasian Medical Publishing Company, Sydney, NSW.